Sumitomo's transdermal blonanserin meets in Phase III for schizophrenia

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported top-line data from a double-blind, international Phase III trial in 580

Read the full 180 word article

User Sign In